Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma

BACKGROUND. Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and trabectedin are licensed for sarcoma treatment from second‐line, but very little and contradictory data are available on their activity in ASPS. Lac...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Stacchiotti, Silvia, Mir, Olivier, Le Cesne, Axel, Vincenzi, Bruno, Fedenko, Alexander, Maki, Robert G., Somaiah, Neeta, Patel, Shreyaskumar, Brahmi, Mehedi, Blay, Jean Y., Boye, Kjetil, Sundby Hall, Kirsten, Gelderblom, Hans, Hindi, Nadia, Martin‐Broto, Javier, Kosela, Hanna, Rutkowski, Piotr, Italiano, Antoine, Duffaud, Florence, Kobayashi, Eisuke, Casali, Paolo G., Provenzano, Salvatore, Kawai, Akira
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2017
Témata:
Sarcomas
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5759809/
https://ncbi.nlm.nih.gov/pubmed/28754721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky